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Conclusions: In patients undergoing noncardiac surgery administra-
tion of aspirin before surgery and throughout the early postsurgical period
has no effect on the rate of a composite of death or nonfatal myocardial
infarction but does increase risk of major bleeding.
Summary: Data from large randomized trials have shown the use of
aspirin can prevent myocardial infarction and major vascular events, with
high-dose aspirin not being superior to low-dose aspirin in preventing
vascular complications, and low-dose aspirin associated with a lower inci-
dence of gastric toxic effects. Among patients undergoing noncardiac sur-
gery there is a large amount of variability in the use of perioperative
aspirin, both among patients who are not already taking aspirin and among
those who are on long-term aspirin treatment. Because of the uncertain risks
and beneﬁts of aspirin in the perioperative period the authors conducted this
trial, POISE-2. The goal was to evaluate the effect of low-dose aspirin as
compared with placebo on the 30-day risk of a composite of death or
nonfatal myocardial infarction among patients undergoing noncardiac sur-
gery. The authors utilize a 2-by-2 factorial trial design, and randomly
assigned 10,010 patients preparing to undergo noncardiac surgery, who
were at risk for vascular complications to receive aspirin or placebo and
clonidine or placebo. This paper reports the results of the aspirin portion
of the trial. Patients were stratiﬁed according to whether or not they were
taking aspirin before the study (initiation stratum, 5628 patients) or they
were already on an aspirin (continuation stratum, 4382 patients). Patients
started taking aspirin (at a dose of 200 mg) or placebo just before surgery
and continued it daily (at a dose of 100 mg) for 30 days in the initiation stra-
tum and for 7 days in the continuation stratum, after which patients
resumed their regular aspirin regimen. The primary outcome was a compos-
ite of death or nonfatal myocardial infarction at 30 days. The primary
outcome occurred in 351 of 4998 patients (7.0%) in the aspirin group
and in 355 of 5012 patients (7.1%) in the placebo group (hazard ration
in the aspirin group 0.99; 95% CI, 0.86-1.15; P ¼ .92). Major bleeding
was more common in the aspirin group than in the placebo group (230 pa-
tients [4.6%] vs 188 patients [3.8%]; hazard ratio, 1.23; 95% CI, 1.01-1.49;
P ¼ .04). Primary and secondary outcome results were similar in the two
aspirin strata. There were also no differences when patients were stratiﬁed
with respect to nonvascular noncardiac surgery or vascular noncardiac sur-
gery or when they were stratiﬁed according to the revised Cardiac Risk In-
dex. There were also no differences in the aspirin and nonaspirin group in
patients with revised Cardiac Rick Index scores ranging from 0 to >4.
Comment: It has been dogma that patients undergoing vascular sur-
gery should be on aspirin to prevent cardiac complications in the periop-
erative period. The data suggests administration of aspirin prior to
noncardiac surgery, including noncardic vascular surgery and then
throughout the early postoperative period has no signiﬁcant effect on
rate of death or nonfatal myocardial infarction, but does increase risk of
bleeding. Therefore, if one chooses to withhold aspirin prior to noncardiac
surgery the question arises how long of time is it necessary to withhold
aspirin therapy. The authors point out that studies suggest hemostasis is
unimpaired if at least 20% of the platelets have normal Cox-1 activity.
This combined with the fact that 12% of circulating platelets are replaced
every 24 hours suggests stopping aspirin 72 or more hours before surgery
may be adequate to minimize risk of perioperative bleeding (Cerskus AL,
et al. Thromb Res 1980;18:389-97 and Bradlow BA, et al. Thromb Res
1982;27:99-110).
Lipidomics Proﬁling and Risk of Cardiovascular Disease in the
Prospective Population-Based Bruneck Study
Stegemann C, Pechlaner R, Willeit P, et al. Circulation 2014;129:1821-31.
Conclusions: Molecular lipid proﬁling is a promising new technique,
potentially better than conventional biochemical measures of lipid classes, to
identify population-based cohorts for increased risk of cardiovascular
disease.532Summary: The authors have identiﬁed previously that lipid proﬁling
of carotid endarterectomy specimens can distinguish between symptomatic
and asymptomatic plaques (Stegemann C et al, Circ Cardiovasc Genet
2011;4:232-42). Mass spectrometry (MS) is the preferred method for in-
depth studies of lipid-related pathomechanisms. MS can screen and simulta-
neously analyze molecular lipid species in nonseparated lipid extracts. In this
study, the authors performed lipidomics proﬁling in the prospective popula-
tion-based Bruneck Study and analyzed the association of 135 distinct lipid
species with cardiovascular disease risk over a 10-year observation period.
Goals were to identify new biomarkers for cardiovascular disease that are
perhaps superior to traditional ones for delineating risk of plaque destabili-
zation, rupture, and ultimately cardiovascular events. Lipids were extracted
from 685 plasma specimens from the Bruneck Study. Baseline evaluations
were performed in 2000. One hundred thirty-ﬁve lipid species from 8
different lipid classes were proﬁled by shotgun lipidomics with the use of
mass spectrometry. Levels of individual species of cholesterol esters (CEs),
lysophosphatidylcholines, phosphatidylcholines, phosphatidylethanolamines
(PEs), sphingomyelins, and triacylglycerols (TAGs) were associated with
cardiovascular disease over a 10-year observation period (2000-2010, 90
incident events). Among the lipid species with the strongest predictive value
were TAGs and CEs with a low carbon number and double-bond content,
including TAG (54:2) and CE (16:1), as well as PE (36:5) (P ¼ 5.1x107,
2.2x104, and 2.5x103, respectively). Consideration of these 3 lipid spe-
cies in addition to traditional risk factors resulted in improved risk discrim-
ination and classiﬁcation for cardiovascular disease (cross-validated DC
index, 0.0210; 95% CI, 0.0010-0.0422). There was also improvement in in-
tegrated discrimination (0.0212; 95% CI, 0.0031-0.0406), as well as
continuous net reclassiﬁcation index (0.398; 95% CI, 0.175-0.619).
Comment: It is well known the bulk of cardiovascular disease risk is
not well explained by traditional risk factors. The study suggests molecular
lipid proﬁling can result in signiﬁcant improvement in cardiovascular risk
discrimination beyond that of classic risk factors. This study is the ﬁrst to
use advanced mass spectrometry-based lipidomics proﬁling, potentially
identifying patients beneﬁting from primary prevention. An increased focus
on molecular lipid proﬁling rather than just classiﬁcation of lipids into classes
may provide improved stratiﬁcation of cardiovascular risk and better identi-
ﬁcation of patients in whom primary prevention is most indicated.
Racial and Regional Differences in Venous Thromboembolism in the
United States in Three Cohorts
Zakai NA, McClure LA, Judd SE, et al. Circulation 2014;129:1502-9.
Conclusions: There are racial and regional differences in venous
thromboembolism rates within the U.S.
Summary: Black Americans are thought to have higher rates of
venous thromboembolism (VTE) than white Americans. While potential
risk factors such as obesity, diabetes mellitus, and elevated factor VIII are
more common in blacks, there are genetic polymorphisms such as factor
V Leiden and the prothrombine gene 20210A mutation that are more com-
mon in whites (Zakai NA and McClure LA. J Thromb Haemost
2011;9:1877-82). The authors point out that previous studies on race
and VTE in the United States have been limited in that they examine
administrative databases, without validation of VTE events, had limited
numbers of black patients, and were from discrete geographic areas, or
excluded outpatient-treated DVTs. For this study, the authors assessed
VTE incidence in blacks and whites in three large cohorts: the Cardiovascu-
lar Health Study (CHS), the Atherosclerosis Risk in Communities Study
(ARIC), and the Reasons for Geographic and Racial Differences in Stroke
study (REGARDS). The studies together have followed up 51,149 individ-
uals over 439,090 person-years and have included 17,318 black Americans.
The association of race with VTE was tested with Cox proportional hazard
models adjusted for VTE risk factors. Over the 438,090 person-years, 916
incident VTE events (302 in blacks) occurred in the 51,149 individuals who
were followed up. With a risk factor-adjusted model, blacks had a higher
rate of VTE than whites in the CHS (hazard ratio, 1.81; 95% CI, 1.20-
2.73) but not ARIC (hazard ratio, 1.21; 95% CI, 0.96-1.54). In REGARDS
there was a signiﬁcant region-by-race interaction (P ¼ .01) with blacks in
